Want to see KR:001060 full AI Analyst Report?
Top Page
JW Pharmaceutical Corporation
(001060)
Select Model
Select Model
Rating:71Outperform
Price Target:
$25,581.00
Action:N/A
Date:10/28/26
The score is driven primarily by strengthening financial performance (higher margins, conservative leverage, and robust free cash flow) and very attractive valuation (low P/E plus a ~2.8% dividend yield). These positives are partially offset by weak technicals, with the stock below key moving averages and negative momentum indicators.
Positive Factors
Improving Profitability
Profitability has improved materially from the lower margins reported in prior years, with strong TTM net, EBIT, and EBITDA margins. This indicates better earnings quality and provides a stronger base for reinvestment, resilience, and sustained returns over the coming quarters.
Negative Factors
Uneven Revenue Growth
Revenue growth has not been consistently strong across the reported period, including a decline in 2024 and only steady TTM expansion. This uneven top-line trajectory may limit operating leverage and makes sustained profit growth more dependent on margins rather than broad-based demand growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Profitability
Profitability has improved materially from the lower margins reported in prior years, with strong TTM net, EBIT, and EBITDA margins. This indicates better earnings quality and provides a stronger base for reinvestment, resilience, and sustained returns over the coming quarters.
Read all positive factors
JW Pharmaceutical Corporation (001060) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩560.29B
Dividend Yield2.8%
Average Volume (3M)31.71K
Price to Earnings (P/E)5.5
Beta (1Y)0.36
Revenue Growth10.50%
EPS Growth96.29%
CountryKR
Employees1,106
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4192.84
Shares Outstanding24,581,533
10 Day Avg. Volume33,315
30 Day Avg. Volume31,711
Financial Highlights & Ratios
PEG Ratio-2.42
Price to Book (P/B)1.67
Price to Sales (P/S)0.79
P/FCF Ratio7.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3,670
Revenue Forecast (FY)₩849.20B
JW Pharmaceutical Corporation Business Overview & Revenue Model
Company Description
JW Pharmaceutical Corporation, established in 1945 and headquartered in Seoul, South Korea, operates globally, focusing on the development, manufacturing, and distribution of a comprehensive range of pharmaceuticals and medical supplies. Its diver...
JW Pharmaceutical Corporation Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
78
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 820.36B | 774.80B | 719.38B | 748.53B | 684.35B | 606.58B |
| Gross Profit | 388.22B | 359.31B | 323.50B | 335.67B | 287.95B | 234.38B |
| EBITDA | 125.75B | 106.62B | 110.17B | 89.35B | 73.10B | 45.13B |
| Net Income | 101.28B | 61.69B | 65.04B | 37.01B | 31.89B | -919.18M |
Balance Sheet | ||||||
| Total Assets | 659.89B | 605.27B | 604.60B | 645.04B | 627.97B | 633.05B |
| Cash, Cash Equivalents and Short-Term Investments | 59.65B | 60.25B | 32.55B | 92.84B | 149.68B | 65.67B |
| Total Debt | 71.75B | 54.63B | 91.73B | 170.28B | 209.54B | 245.14B |
| Total Liabilities | 249.96B | 235.90B | 275.11B | 379.60B | 402.21B | 444.51B |
| Stockholders Equity | 409.94B | 369.37B | 329.49B | 265.44B | 240.35B | 201.19B |
Cash Flow | ||||||
| Free Cash Flow | 114.20B | 84.62B | 51.25B | 46.45B | 44.41B | 5.22B |
| Operating Cash Flow | 134.48B | 96.40B | 79.39B | 87.16B | 56.76B | 18.12B |
| Investing Cash Flow | -65.13B | -7.20B | 14.08B | -63.83B | -18.92B | -22.87B |
| Financing Cash Flow | -36.55B | -59.78B | -100.19B | -41.19B | -36.91B | 27.20B |
JW Pharmaceutical Corporation Technical Analysis
Negative
―
Price Trends
26557.00
Negative
25840.50
Negative
28146.34
Negative
Market Momentum
-897.53
Positive
31.70
Neutral
3.51
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:001060, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 25365.00, equal to the 50-day MA of 26557.00, and equal to the 200-day MA of 28146.34, indicating a bearish trend. The MACD of -897.53 indicates Positive momentum. The RSI at 31.70 is Neutral, neither overbought nor oversold. The STOCH value of 3.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:001060.
JW Pharmaceutical Corporation Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩560.29B | 5.53 | ― | 2.80% | 10.50% | 96.29% | |
61 Neutral | ₩581.17B | 6.94 | ― | 1.94% | 10.06% | -3.74% | |
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₩435.39B | -884.82 | ― | 0.08% | 6.21% | 95.65% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― |
* General Sector Average
KR:001060
JW Pharmaceutical Corporation
23,200.00
191.16
0.83%
KR:000640
Dong-A Socio Holdings Co., Ltd.
87,600.00
-18,769.28
-17.65%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
95.20
2.60%
KR:019170
Shinpoong Pharmaceutical Co., Ltd.
8,460.00
-5,550.00
-39.61%
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-8,968.36
-20.44%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-10,206.94
-44.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.